Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | EV-302: 1L enfortumab vedotin in combination with pembrolizumab

Richard Cathomas • 5 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer Enfortumab vedotin Pembrolizumab
EV-302

Richard Cathomas, MD, PhD, Hospital Graubünden, Chur, Switzerland, reflects on first-line (1L) therapies for patients with metastatic urothelial carcinoma, including EV-302 (NCT04223856) which is evaluating enfortumab vedotin in combination with pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Richard Cathomas

0:37
Bladder-sparing approaches in muscle-invasive urothelial carcinoma
Richard Cathomas • 5 Jun 2022
0:46
UC highlights at ASCO 2022
Richard Cathomas • 5 Jun 2022
1:18
Primary analysis of SAKK 06/17: perioperative chemoimmunotherapy with durvalumab for operable MIUC
Richard Cathomas • 5 Jun 2022
2:34
First-line treatments for patients with mHSPC and mCRPC
Richard Cathomas • 27 Sep 2021

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals